Preparation and physicochemical characterization of amoxicillin β-cyclodextrin complexes

AAPS PharmSciTech

Volumn 11, Issue 2, 2010, Pages 574-581

  Bisson Boutelliez, Catherine ^a   Fontanay, Stephane ^a,b   Finance, Chantal ^a,b   Kedzierewicz, Francine ^a,b  

^a NANCY UNIVERSITÉ   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Cyclodextrin; Amoxicillin; Complex; DSC TG SM; FT IR; HPLC stability constant; NMR

Indexed keywords

AMOXICILLIN; BETA CYCLODEXTRIN; CARBOXYL GROUP; PHENYL GROUP; ANTIINFECTIVE AGENT; BETA CYCLODEXTRIN DERIVATIVE; EXCIPIENT; FOOD ADDITIVE;

ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; INFRARED SPECTROSCOPY; MASS SPECTROMETRY; NUCLEAR OVERHAUSER EFFECT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SOLID STATE; STOICHIOMETRY; THERMOGRAVIMETRY; CHEMISTRY; DRUG FORMULATION; DRUG STABILITY; PROCEDURES; SYNTHESIS;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; BETA-CYCLODEXTRINS; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; FOOD ADDITIVES;

EID: 77954816345     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9412-1     Document Type: Article

References (32)

1. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. J Am Dent Assoc. 2007;138(739-45):747-60.
2. Bresco-Salinas M, Costa-Riu N, Berini-Aytes L, Gay-Escoda C. Antibiotic susceptibility of the bacteria causing odontogenic infections. Med Oral Patol Oral Cir Bucal. 2006;11: E70-5.
3. Hansmann Y. Treatment and prevention of Lyme disease. Curr Probl Dermatol. 2009;37:111-29.
4. Kuriyama T, Williams DW, Yanagisawa M, Iwahara K, Shimizu C, Nakagawa K, et al. Antimicrobial susceptibility of 800 anaerobic isolates from patients with dentoalveolar infection to 13 oral antibiotics. Oral Microbiol Immunol. 2007;22:285-8.
5. Drissi M, Ahmed ZB, Dehecq B, Bakour R, Plesiat P Hocquet D. Antibiotic susceptibility and mechanisms of beta-lactam resistance among clinical strains of Pseudomonas aeruginosa: first report in Algeria. Med Mal Infect. 2008;38:187-91.
6. Handal T, Olsen I, Walker CB, Caugant DA. Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005;242:319-24.
7. Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen HE, Hoiby N. Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob Agents Chemother. 2009;53:2483-91.
8. Shrestha B. Study of beta lactamase activity of Staphylococcus aureus isolated from healthy nasal carriers and hospital isolates. Nepal Med Coll J. 2007;9:107-10.
9. Voha C, Docquier JD, Rossolini GM, Fosse T. Genetic and biochemical characterization of FUS-1 (OXA-85), a narrowspectrum class D beta-lactamase from Fusobacterium nucleatum subsp. polymorphum. Antimicrob Agents Chemother. 2006;50:2673-9.
10. Kaner D, Christan C, Dietrich T, Bernimoulin JP, Kleber BM, Friedmann A. Timing affects the clinical outcome of adjunctive systemic antibiotic therapy for generalized aggressive periodontitis. J Periodontol. 2007;78:1201-8.
11. Moeintaghavi A, Talebi-ardakani MR, Haerian-ardakani A, Zandi H, Taghipour S, Fallahzadeh H, et al. Adjunctive effects of systemic amoxicillin and metronidazole with scaling and root planing: a randomized, placebo controlled clinical trial. J Contemp Dent Pract. 2007;8:51-9.
12. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Metaanalysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2008;28:868-77.
13. Szejtli J. Cyclodextrin Technology. Dordrecht: Kluwer; 1988.
14. Aleem O, Kuchekar B, Pore Y, Late S. Effect of beta-cyclodextrin and hydroxypropyl beta-cyclodextrin complexation on physicochemical properties and antimicrobial activity of cefdinir. J Pharm Biomed Anal. 2008;47:535-40.
15. Beni S, Szakacs Z, Csernak O, Barcza L, Noszal B. Cyclodextrin/imatinib complexation: binding mode and charge dependent stabilities. Eur J Pharm Sci. 2007;30:167-74.
16. Figueiras A, Sarraguca JM, Carvalho RA, Pais AA, Veiga FJ. Interaction of omeprazole with a methylated derivative of beta-cyclodextrin: phase solubility, NMR spectroscopy and molecular simulation. Pharm Res. 2007;24:377-89.
17. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev. 1998;98:2045-76.
18. Pajatsch M, Andersen C, Mathes A, Bock A, Benz R, Engelhardt H. Properties of a cyclodextrin-specific, unusual porin from Klebsiella oxytoca. J Biol Chem. 1999;274:25159-66.
19. Pajatsch M, Gerhart M, Peist R, Horlacher R, Boos W, Bock A. The periplasmic cyclodextrin binding protein CymE from Klebsiella oxytoca and its role in maltodextrin and cyclodextrin transport. J Bacteriol. 1998;180:2630-5.
20. Aki H, Niiya T, Iwase Y, Kawasaki Y, Kumai K, Kimura T. Multimodal inclusion complexes of ampicillin with β-cyclodextrins in aqueous solution. Thermochim Acta. 2004;416:87-92.
21. Athanassiou G, Michaleas S, Lada-Chitiroglou E, Tsitsa T, Antoniadou-Vyza E. Antimicrobial activity of beta-lactam antibiotics against clinical pathogens after molecular inclusion in several cyclodextrins. A novel approach to bacterial resistance. J Pharm Pharmacol. 2003;55:291-300.
22. Maffeo D, Leondiadis L, Mavridis IM, Yannakopoulou K. Positive effect of natural and negatively charged cyclodextrins on the stabilization of penicillins towards beta-lactamase degradation due to inclusion and external guest-host association. An NMR and MS study. Org Biomol Chem. 2006;4:1297-304.
23. The Merck Index. In Windholz M., Budavari S., Blumetti R. F., Otterbein E. S., editors. Tenthed. Merck and Co., Inc. 1996.
24. Higuchi T, Connors KA. Advances in analytical chemistry and instrumentation. New York: Wiley Interscience; 1965. p. 117-212.
25. Claridge T D W. High resolution NMR techniques in organic chemistry. Oxford: Pergamon; 1999. p. 320-36.
26. Uekama K, Hirayama F, Irie T. The new method for determination of the stability constants of cyclodextrin-prostaglandin inclusion complexes by liquid chromatography. Chemistry Letters. 1978; p. 661-664.
27. Di Stefano R, Scopelliti M, Pellerito C, Fiore T, Vitturi R, Colomba MS, et al. Organometallic complexes with biological molecules. XVII. Triorganotin (IV) complexes with amoxicillin and ampicillin. J Inorg Biochem. 2002;89:279-92.
28. Fogazzi GB, Cantu M, Saglimbeni L, Daudon M. Amoxycillin, a rare but possible cause of crystalluria. Nephrol Dial Transplant. 2003;18:212-4.
29. Mc Millan I, Stoodley RJ. A novel rearrangement of methyl-6 chloropenicillanate. Tetrahydron Lett. 1966;11:1205-10.
30. Marciniec B, Plotkowiak Z, Wachowski L, Kozak M, Popielarz-Brzezinska M. Analytical study of γ-irradiated antibiotics in the solid state. J Therm Anal Calorim. 2002;68:423-36.
31. Szejtli J. Inclusion compounds: physical properties and applications. In: Atwood JL, Davies JE, MacNicol DD, editors. Inclusion compounds, vol. 3. London: Academic; 1984. p. 331-89.
32. Nepogodiev SA, Stoddart JF. Cyclodextrin-based catenanes and rotaxanes. Chem Rev. 1998;98:1959-76.